PCSK9 and peeling skin syndrome: In pSS patients, no significant correlation was found between plasma PCSK9 levels and either IMTmax, IMTmean, bFMD, or aPWV, even when accounting for the potential confounding effect of ongoing therapy with either corticosteroids/immunomodulators (r = 0.106, p = 0.462; r = 0.128, p = 0.375; r = −0.073, p = 0.622; r = −0.062, p = 0.672) or statins (r = 0.102, p = 0.480; r = 0.124, p = 0.390; r = 0.054, p = 0.714; r = −0.044, p = 0.765).